Study
Opening the study…
Study
Opening the study…
There’s a newer version. You’re reading v1, and its author has corrected it since. Claims that didn’t change keep their verification.
Read v2, the newestThe studies most like this one, by the words that set it apart, then the fields they share and the work they cite.
Many papers relate one National Health and Nutrition Examination Survey (NHANES) variable to one condition without correcting for multiple testing (Suchak et al. (2025)). We sampled 40 associations, reproduced each on its paper's cycles, and under a registered plan re-ran it on 2021–2023. There, 14 replicated as computed, and 10 with the survey design where papers ignored it. Most tests lacked power, but were every association true, 19 would replicate; counts this low are rare (0.047, or 0.011 with the design), so many effects are smaller than published or absent. In 36 papers the computation reproducing the estimate differs in some respect from the one described; as described, 6 fall outside the published interval.
An observational atlas linked GLP-1 receptor agonists to dozens of outcomes beyond glucose, weight and the heart. We pooled the serious adverse events that 234 placebo-controlled trials, with 161309 participants, posted to ClinicalTrials.gov, coded blind to the results under a registered plan. Reports of serious bacterial infection (ratio 0.88, confidence interval 0.83 to 0.93) and pneumonia (0.87) were less frequent on the drugs, as were pneumonia counted in people and death. The reductions held under random effects, with any trial left out, if infection terms overlapped within participants as all serious events do in each comparison, and in trials not coded as recording only on treatment. Of the atlas's associations with enough events to test, the trials found three in its direction with no difference from it detected, contradicted none, and left most inconclusive, among them every neurological and psychiatric one; its large hazard of drug-induced pancreatitis concerns a subtype the trials don't separate.
Nobody had pooled serious adverse events across vaccines' placebo-controlled trials. We took every randomized trial of a preventive vaccine against placebo with results posted on ClinicalTrials.gov, 491 trials with 1,133,392 participants, coded blind to counts under a plan registered before any arm was compared. Vaccine recipients had a serious adverse event about as often as placebo recipients (risk ratio 0.98, confidence interval 0.96 to 1.01; at most +3.8 per 10,000 more on vaccine) and died about as often (0.96, 0.91 to 1.01): both intervals lie inside the registered margins, though neither reading passes the registered robustness rule. Against placebos stated to be inert the ratio was 1.00, as it was for aluminium-adjuvanted vaccines; for mRNA vaccines the interval was wider. No named outcome or organ system differed after correction. Across different trials, uncorrected, live vaccines were followed by fewer serious infections outside their target than non-live ones. A pool like this cannot see rare harms, and some registry tables follow vaccine groups longer than placebo groups.